SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-361346
Filing Date
2021-12-17
Accepted
2021-12-17 17:17:03
Documents
16
Period of Report
2021-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d251277d8k.htm   iXBRL 8-K 26924
2 EX-1.1 d251277dex11.htm EX-1.1 190352
3 EX-5.1 d251277dex51.htm EX-5.1 13204
7 GRAPHIC g251277g57i48.jpg GRAPHIC 2359
8 GRAPHIC g251277g85y16.jpg GRAPHIC 3883
  Complete submission text file 0001193125-21-361346.txt   420048

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA onct-20211217.xsd EX-101.SCH 2895
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE onct-20211217_lab.xml EX-101.LAB 18139
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE onct-20211217_pre.xml EX-101.PRE 11410
9 EXTRACTED XBRL INSTANCE DOCUMENT d251277d8k_htm.xml XML 3365
Mailing Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

IRS No.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 211502640
SIC: 2834 Pharmaceutical Preparations